To interrogate the underlying effect of CD101 in glioma, we carried out functional enrichment analyses based on DEGs between patients with a high or low expression level of CD101, in which a total of 2,469 DEGs were identified accordingly, with 2,052 upregulated and 417 downregulated genes (Figures 5A, B). The gene discussed is CD101; the disease is central nervous system cancer.